Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antipneumococcal activity of dalbavancin compared to other agents.

Literature DB >> 16304200

Antipneumococcal activity of dalbavancin compared to other agents.

Gengrong Lin¹, Kathy Smith, Lois M Ednie, Peter C Appelbaum.

Abstract

Against 307 pneumococci of various resistotypes, dalbavancin MICs were 0.008 to 0.125 microg/ml. All strains were susceptible to vancomycin, teicoplanin, linezolid, and quinupristin-dalfopristin. Dalbavancin at 2x MIC was bactericidal against all 10 pneumococci tested after 24 h. Vancomycin and teicoplanin killed 10 and 8 strains, respectively, at 2x MIC after 24 h.

Entities: Chemical

Mesh：

Substances：

Year: 2005 PMID： 16304200 PMCID： PMC1315967 DOI： 10.1128/AAC.49.12.5182-5184.2005

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

23 in total

1. Antipneumococcal activities of gemifloxacin compared to those of nine other agents.

Authors: T A Davies; L M Kelly; G A Pankuch; K L Credito; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 2000-02 Impact factor: 5.191

2. Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity.

Authors: Tamara R Anderegg; Douglas J Biedenbach; Ronald N Jones
Journal: J Clin Microbiol Date: 2003-06 Impact factor: 5.948

3. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

Authors: E Cercenado; F García-Garrote; E Bouza
Journal: J Antimicrob Chemother Date: 2001-01 Impact factor: 5.790

4. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

Authors: C J Henwood; D M Livermore; A P Johnson; D James; M Warner; A Gardiner
Journal: J Antimicrob Chemother Date: 2000-12 Impact factor: 5.790

5. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

Authors: D K Chen; A McGeer; J C de Azavedo; D E Low
Journal: N Engl J Med Date: 1999-07-22 Impact factor: 91.245

6. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.

Authors: Michael R Jacobs; David Felmingham; Peter C Appelbaum; Reuben N Grüneberg
Journal: J Antimicrob Chemother Date: 2003-07-15 Impact factor: 5.790

7. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.

Authors: Jennifer M Streit; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal: Diagn Microbiol Infect Dis Date: 2004-02 Impact factor: 2.803

8. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria.

Authors: Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi Warren; Kerin Tyrrell; Helen T Fernandez
Journal: Antimicrob Agents Chemother Date: 2003-06 Impact factor: 5.191

9. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

Authors: Elyse Seltzer; Mary Beth Dorr; Beth P Goldstein; Marc Perry; James A Dowell; Tim Henkel
Journal: Clin Infect Dis Date: 2003-10-17 Impact factor: 9.079

10. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent.

Authors: R N Jones; D J Biedenbach; D M Johnson; M A Pfaller
Journal: J Chemother Date: 2001-06 Impact factor: 1.714

4 in total

1. Dalbavancin (zeven), a novel glycopeptide for resistant gram-positive organisms.

Authors: Jennifer Colabella; Larisa Chagan
Journal: P T Date: 2008-01

2. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.

Authors: Henry S Heine; Bret K Purcell; Jennifer Bassett; Lynda Miller; Beth P Goldstein
Journal: Antimicrob Agents Chemother Date: 2010-01-04 Impact factor: 5.191

3. Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).

Authors: Ronald N Jones; Jason E Schuchert; Rodrigo E Mendes
Journal: Antimicrob Agents Chemother Date: 2016-05-23 Impact factor: 5.191

Review 4. Dalbavancin: a novel antimicrobial.

Authors: A Y Chen; M J Zervos; J A Vazquez
Journal: Int J Clin Pract Date: 2007-03-16 Impact factor: 2.503

4 in total